Summit Therapeutics Inc.

Good afternoon and welcome to Summit Therapeutics Q2 2026 earnings call. All participants will be in listen-only mode until the question and answer portion of this call. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's website for updates Good afternoon.

and thank you for joining us. On today's call, we will provide an update on our second quarter 2026 financial results and operational progress. This afternoon's press release is available on our website, www.smmtcx.com. Our form 10Q was also filed today and is available on our website and via the SEC's website. Today's call is being simultaneously webcast and an archived replay will also be made available later today on our website. Joining me on the call today is Bob Duggan, our Chairman of the Board and Co-Chief Executive Officer, Dr. Maki Zanganeh, our President and Co-Chief Executive Officer, Manmeet Soni, our Chief Operating Officer and Chief Financial Officer, and Dr. Allen Yang, Chief of R&D Strategy. I'm Dave Gancarz, the Chief Business and Strategy Officer here at Summit. Before we get started with the rest of the call, I would like to note that some statements made by our management team and some responses to questions that we make today may be considered forward-looking statements based on our current expectations. Summit caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information, including the Form 10Q issued today, about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements, except as required by law. One item of note, this presentation is being webcast with slides, so we'll be referring to the slide being displayed in the web link. I'd encourage you to use the webcast link to see the slides being presented this afternoon that will accompany our comments. Following comments from our team, we will take questions. And with that, I'll hand it over to Bob.

Thank you, Dave. Good afternoon, everyone. Thank you for joining us today. I'm very proud of the highly focused, mission-driven, patient-first team at Summit and their growing physician support around Avenisumab, our PD-1, VEGF, bispecific, and lead investigational asset. In addition, we continue to appreciate Big Pharma Thank you for joining us. I'd like to take a moment to remind those of you who have been with us from the beginning and introduce to those of you who may be new to the story of what Ivernissimab has accomplished to date. You can see this on slide three. Ivernissimab has read out four phase three clinical studies to date, all four with positive data. This has led to two approvals in China so far with one currently under review, in addition to the pending BLA with the U.S. FDA. A total of 15 Phase III trials are currently ongoing or have read out in multiple tumor types. Between Summit and our partners at Keso, 52 clinical trials have been initiated evaluating Ibenizumab in a variety of solid tumors. When including investigator-initiated and collaborative studies, a total of 171 clinical trials are now listed on clinicaltrials.gov. The enthusiasm demonstrated by investigators around the world to generate data and sync positive signals for patients facing high-end medical needs really speaks to the opportunity and ever-present optimism surrounding Ibenizumab. Together with the KESO, over 4,000 patients in either summit-sponsored or KESO-sponsored clinical trials across the world have been dosed with Ibenizumab. Commercially, in China, over 70,000 patients have been administered Ivanisimab. On slide four, we see a snapshot of the current Ivanisimab development plans across Summit and the Kessel, as well as a phase three clinical trial sponsored by a prominent European cooperative group, Gortec. Our collective pipelines cover not only multiple settings in lung and colorectal cancers, but also head and neck, breast, biliary, pancreatic, gynecological, gastric, and hepatocellular Thank you very much. Thank you, Bob. Yesterday, we announced an updated OS analysis conducted for our global Phase 3 Harmony trials.